← All trials
NCT04556552
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 13, 2020
- Primary completion
- Jun 15, 2022
- Completion date
- Aug 1, 2022
- First posted
- Sep 21, 2020
- Last posted
- Nov 17, 2020
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Emory UniversityLead sponsor
- National Institute on Drug Abuse (NIDA)Collaborator
- Emory UniversityReponsible party - principal investigator
- Emory UniversityOverall official - principal investigator
- Georgia Institute of TechnologyCollaborator
- City University of New YorkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.